Clinical Pharmacy Activities in Chronic Kidney Disease and End-Stage Renal Disease Patients
Author Information
Author(s): Gunar Stemer, Rosa Lemmens-Gruber
Primary Institution: University of Vienna
Hypothesis
The study aims to summarize the available evidence regarding the role and impact of clinical pharmacy services for chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients.
Conclusion
Clinical pharmacy services have a positive impact on patient care in CKD and ESRD patients, although high-quality evidence is limited.
Supporting Evidence
- Clinical pharmacy services improved disease-oriented outcomes like haemoglobin levels.
- 79% of clinical pharmacist interventions were accepted by physicians.
- Clinical pharmacists managed common comorbidities like anaemia effectively.
Takeaway
Clinical pharmacists help patients with kidney problems by making sure they take the right medicines and understand how to manage their health better.
Methodology
A systematic literature review was conducted using Medline, Embase, and International Pharmaceutical Abstracts databases to identify relevant studies.
Potential Biases
Potential publication bias and lack of data on rejected interventions may affect the findings.
Limitations
Few high-quality trials exist, and many studies were descriptive or observational rather than controlled.
Participant Demographics
The majority of studies were conducted in the United States, primarily involving patients undergoing hemodialysis.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website